Abstract
Purpose
The aim of this study was to assess the effects of acyclic retinoid (ACR) and vitamin K2 (VK2) in HL-60 cells.
Methods
We used HL-60 cells, and the Trypan Blue dye exclusion method was used for cell proliferation assays. For detection of apoptosis, the Annexin V–binding capacity of treated cells was examined by flow cytometry. To evaluate the cell cycle, we used a FITC BrdU Flow KIT and flow cytometry. Total extracted and equivalent amounts of protein were examined by Western blotting using specific antibodies.
Results
ACR and VK2 dose dependently inhibited the proliferation of HL-60 cells. These two agents in combination synergistically inhibited cell growth and induced apoptosis. VK2 inhibited activation of the Ras/MAPK signaling pathway, and ACR plus VK2 cooperatively inhibited phosphorylation of RXRα and the growth of HL-60 cells. Moreover, ACR and VK2 induced increases in G0/G1 phase HL-60 cells, alone and synergistically in combination.
Conclusion
The synergistic effects of ACR and VK2 on HL-60 cells may provide a novel strategy for treating leukemia.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Adachi S, Okuno M, Matsushima-Nishiwaki R, Takano Y, Kojima S, Friedman SL, Moriwaki H, Okano Y (2002) Phosphorylation of retinoid X receptor suppresses its ubiquitination in human hepatocellular carcinoma. Hepatology 35:332–340
Altucci L, Gronemeyer H (2001) The promise of retinoid to fight against cancer. Nat Rev Cancer 1:181–193
Breitman TR, Selonick SE, Collins SJ (1980) Induction of differentiation of the human promyelocytic leukemia cell line (HL-60) by retinoic acid. Proc Natl Acad Sci USA 77:2936–2940
Chmbon P (1996) A decade of molecular biology of retinoid acid receptors. Faseb J 10:940–954
Collins SJ, Robertson KA, Mueller L (1990) Retinoic acid-induced granulocytic differentiation of HL-60 myeloid leukemia cells is mediated directly through the retinoic acid receptor (RAR-alpha). Mol Cel Biol 10:2154–2163
Dean PN, Dolbeare F, Grantzer H, Rice GC, Gray JW (1984) Cell-cycle analysis using a monoclonal antibody to BrdUrd. Cell Tissue Kinet 17:427–436
Fujita H, Tomiyama J, Tanaka T (1998) Vitamin K2 combined with all-trans retinoic acid induced complete remission of relapsing acute promyelocytic leukemia. Br J Haematol 103:584–585
Hitomi M, Yokoyama F, Mita Y, Nonomura T, Masaki T, Yoshiji H, Inoue H, Kinikawa F, Kurokohchi K, Uchida N, Watanabe S, Kuriyama S (2005) Antitumor effects of vitamins K1, K2, and K3 on hepatocellular carcinoma in vitro and in vivo. Int J Oncol 26:713–720
Kanamori T, Shimizu M, Okuno M, Matsushima-Nishiwaki R, Tsurumi H, Kojima S, Moriwaki H (2007) Synergistic growth inhibition by acyclic retinoid and vitamin K2 in human hepatocellular carcinoma cells. Cancer Sci 98:431–437
Kanemura N, Tsurumi H, Okuno M, Matsushima-Nishiwaki R, Shimizu M, Moriwaki H (2008) Retinoid X receptor alpha is highly phosphorylated in retinoic acid-resistant HL-60R cells and the combination of 9-cis retinoic acid plus MEK inhibitor induces apoptosis in the cells. Leuk Res 32:884–892
Kuriyama S, Hitomi M, Yoshiji H, Nonomura T, Tsujimoto T, Mitoro A, Akahane T, Ogawa M, Nakai S, Deguchi A, Masaki T, Uchida N (2005) Vitamins K2, K3, and K5 exert in vivo antitumor effects on hepatocellular carcinoma by regulating the expression of G1 phase-related cell cycle molecules. Int J Oncol 27:505–511
Matsushima-Nishiwaki R, Shidoji Y, Nishiwaki S, Yamada T, Moriwaki H, Muto Y (1996) Aberrant metabolism of retinoid X receptor proteins in human hepatocellular carcinoma. Mol Cell Endocrinol 121:179–190
Matsushima-Nishiwaki R, Okuno M, Adachi S, Sano T, Akita K, Moriwaki H, Friedman SL, Kojima S (2001) Phosphorylation of retinoid X receptor alpha at serine 260 impairs its metabolism and function in human hepatocellular carcinoma. Cancer Res 61:7675–7682
Matsushima-Nishiwaki R, Okuno M, Takano Y, Kojima S, Friedman SL, Moriwaki H (2003) Molecular mechanism for growth suppression of human hepatocellular carcinoma cells by acyclic retinoid. Carcinogenesis 24:1353–1359
Mehta K, McQueen T, Neamati N, Collins S, Andreeff M (1996) Activation of retinoid receptors RAR alpha and RXR alpha induces differentiation and apoptosis, respectively, in HL-60 cells. Cell Growth Differ 7:179–186
Miyazawa K, Nishimaki J, Ohyashiki K, Enomoto S, Kuriya S, Fukuda R, Hotta T, Teramura M, Mizoguchi H, Uchiyama T, Omine M (2000) Vitamin K2 therapy for myelodysplastic syndromes (MDS) and post-MDS acute myeloid leukemia: information through a questionnaire survey of multi-center pilot studies in Japan. Leukemia 14:1156–1157
Miyazawa K, Yaguchi M, Funato K, Gotoh A, Kawanishi Y, Nishizawa Y, You A, Ohyashiki K (2001) Apoptosis/differentiation-inducing effects of vitamin K2 on HL-60 cells: dichotomous nature of vitamin K2 in leukemia cells. Leukemia 15:1111–1117
Mizuta T, Ozaki I, Eguchi Y, Yasutake T, Kawazoe S, Fujimoto K, Yamamoto K (2006) The effect of menatetrenone, a vitamin K2 analog, on disease recurrence and survival in patients with hepatocellular carcinoma after curative treatment: a pilot study. Cancer 106:867–872
Muto Y, Moriwaki H (1984) Antitumor activity of vitamin A and its derivatives. J Natl Cancer Inst 73:1389–1393
Muto Y, Moriwaki H, Ninomiya M, Adachi S, Saito A, Takasaki KT, Tanaka T, Tsurumi K, Okuno M, Tomita E, Nakamura T, Kojima T (1996) Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. N Engl J Med 334:1561–1567
Muto Y, Moriwaki H, Saito A (1999) Prevention of second primary tumors by an acyclic retinoid in patients with hepatocellular carcinoma. N Engl J Med 340:1046–1047
Nagy L, Thomazy VA, Shipley GL, Fresus L, Lamph W, Heyman RA, Chandraratna RA, Davies PJ (1995) Activation of retinoid X receptors induces apoptosis in HL-60 cell lines. Mol Cell Biol 15:3540–3551
Nakamura N, Shidoji Y, Yamada Y, Hatakeyama H, Moriwaki H, Muto Y (1995) Induction of apoptosis by acyclic retinoid in the human hepatoma-derived cell line, HuH-7. Biochem Biophy Res Commun 207:382–388
Sakai I, Hashimoto S, Yoda M, Hida T, Ohsawa S, Nakajo S, Nakaya K (1994) Novel role of vitamin K2: a potent inducer of differentiation of various human myeloid leukemia cell lines. Biochem Biophys Res Commun 205:1305–1310
Shimizu M, Suzui M, Deguchi A, Lim JT, **ao D, Hayes JH, Papadopoulos KP, Weinstein IB (2004) Synergistic effect of acyclic retinoid and OSI-461 on growth inhibition and gene expression in human hepatoma cells. Clin Cancer 10:6710–6721
Soriano AF, Helfrich B, Chan DC, Heasley LE, Bunn PA, Chou JR (1999) Synergistic effects of new chemopreventive agents and conventional cytotoxic agents against human lung cancer cell lines. Cancer Res 59:6178–6184
Suzui M, Masuda M, Lim JT, Albanese C, Pestell RG, Weinstein IB (2002) Growth inhibition of human hepatoma cells by acyclic retinoid is associated with induction of p21 (CIP1) and inhibition of expression of cyclin D1. Cancer Res 62:3997–4006
Takai K, Okuno M, Yasuda L, Matsushima-Nishiwaki R, Uematsu T, Tsurumi H, Shiratori Y, Muto Y, Moriwaki H (2005) Prevention of second primary tumors by an acyclic retinoid in patients with hepatocellular carcinoma. Updated analysis of the long-term follow-up data. Intervirology 48:39–45
Takami A, Nakao S, Ontachi Y, Yamauchi H, Matsuda T (1999) Successful therapy of myelodysplastic syndrome with menatetrenone, a vitamin K2 analog. Int J Hematol 69:24–26
Tsurumi H, Tojo A, Takahashi T, Ozawa K, Moriwaki H, Asano S, Muto Y (1993) Differentiation induction of human promyelocytic leukemia cells by acyclic retinoid (polyprenoic acid). Int J Hematol 59:9–15
van den Eijnde SM, Luijsterburg AJ, Boshart L, De Zeeuw CI, van Dierendonck JH, Reutelingsperger CP, Vermeji-Keers C (1997) In situ detection of apoptosis during embryogenesis with annexin V: from whole mount to ultrastructure. Cytometry 29:313–320
Watanabe M, Hitomi M, van der Wee K, Rothenberg F, Fisher SA, Zucker R, Svoboda KK, Goldsmith EC, Heiskanen KM, Nieminen AL (2002) The pros and cons of apoptosis assays for use in the study of cells, tissues, and organs. Microsc Microanal 8:375–391
Yaguchi M, Miyazawa K, Katagiri T, Nishimaki J, Kizaki M, Tohyama K, Toyama K (1997) Vitamin K2 and its derivatives induce apoptosis in leukemia cells and enhance the effect of all-trans retinoic acid. Leukemia 11:779–787
Yaguchi M, Miyazawa K, Otawa M, Katagiri T, Nishiwaki J, Ushida Y, Iwase O, Gotoh A, Kawanishi Y, Toyama K (1998) Vitamin K2 selectively induces apoptosis of blastic cells in myelodysplastic syndrome: flow cytometric detection of apoptotic cells using APO2.7 monoclonal antibody. Leukemia 12:1392–1397
Yaguchi M, Miyazawa K, Otawa M, Ito Y, Kawanishi Y, Toyama K (1999) Vitamin K2 therapy for a patient with myelodysplastic syndrome. Leukemia 13:144–145
Yamazaki K, Shimizu M, Okuno M, Matsushima-Nishiwaki R, Kanemura N, Araki H, Tsurumi H, Kojima S, Weinstein IB, Moriwaki H (2007) Synergistic effects of RXR alpha and PPAR gamma ligands to inhibit growth in human colon cancer cells—phosphorylated RXR alpha is a critical target for colon cancer management. Gut 56:1557–1563
Yasuda I, Shiratori Y, Adachi S, Obora A, Takemura M, Okuno M, Shidoji Y, Seishima M, Muto Y, Moriwaki H (2002) Acyclic retinoid induces partial differentiation, down-regulates telomerase reverse transcriptase mRNA expression and telomerase activity, and induces apoptosis in human hepatoma-derived cell lines. J Hepatol 36:660–671
Conflict of interest
None.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kitagawa, J., Hara, T., Tsurumi, H. et al. Synergistic growth inhibition in HL-60 cells by the combination of acyclic retinoid and vitamin K2 . J Cancer Res Clin Oncol 137, 779–787 (2011). https://doi.org/10.1007/s00432-010-0938-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00432-010-0938-0